Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

HomeRunHitterXXXXX May. 12 at 8:01 PM

$PULM scumbags couldn’t close it red today ya bunch of losers 😂

1 · Reply

Nakom May. 12 at 7:31 PM

$PULM You can’t tell me this stock is not being manipulated. Total BS.

0 · Reply

MinnieSteve3 May. 11 at 8:31 PM

$PULM Short interest rises from 19,602 shares on April 15 to 40,413 shares as of April 30. Granted, it's not huge but with the low daily trade volume it can dampen the share price.

1 · Reply

Nakom May. 11 at 6:05 PM

$PULM Couldn’t resist. Just picked up another 150 shares. I think big Pharma is going to be buying delivery platforms this year. JMO.

0 · Reply

Nakom May. 11 at 4:31 PM

$PULM I think with LQDA 1st quarter call Pulmatrix assets just got a whole lot more valuable. DPI is the way to go and a major Pharma is going to want the platform. JMO

1 · Reply

HomeRunHitterXXXXX May. 11 at 12:15 PM

$PULM stock is trading at its cash value

1 · Reply

texrex1230 May. 8 at 9:52 PM

$PULM Any idea on when the Shareholders meeting will be so we can approve the merger?

1 · Reply

Vinniesb May. 8 at 2:01 PM

$PULM Good Luck to whoever is trying to snag 20K shares on the bid!

1 · Reply

MinnieSteve3 May. 8 at 12:49 PM

$PULM a very quiet week. Something has to happen sometime.

1 · Reply

HomeRunHitterXXXXX May. 5 at 7:56 PM

$PULM up 6 cents on 34k volume not good

1 · Reply

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

2026-03-26T12:10:12.000Z - 6 weeks ago

Pulmatrix to merge with Eos Senolytix

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

2026-03-02T13:06:59.000Z - 2 months ago

Pulmatrix announces Cullgen terminates merger agreement

Mar 2, 2026, 8:00 AM EST - 2 months ago

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Feb 26, 2026, 8:05 AM EST - 2 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

2025-12-18T13:17:12.000Z - 5 months ago

Pulmatrix and Cullgen continue to pursue merger

Dec 18, 2025, 8:05 AM EST - 5 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

2025-10-16T12:21:23.000Z - 7 months ago

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

2025-10-16T12:10:51.000Z - 7 months ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Oct 16, 2025, 8:05 AM EDT - 7 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

2025-08-06T12:16:43.000Z - 10 months ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Aug 6, 2025, 8:05 AM EDT - 10 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

2025-06-25T15:20:32.000Z - 11 months ago

Pulmatrix trading resumes

2025-06-25T15:15:23.000Z - 11 months ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:34:11.000Z - 11 months ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:33:41.000Z - 11 months ago

Pulmatrix trading resumes

May 15, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 1 year ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

2024-11-13T14:50:17.000Z - 1 year ago

Pulmatrix trading resumes

2024-11-13T14:07:00.000Z - 1 year ago

Pulmatrix announces merger agreement with Cullgen

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

2024-11-13T13:55:15.000Z - 1 year ago

Pulmatrix trading halted, news pending

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Transcript: M&A Announcement

2024-11-08T15:35:37.000Z - 1 year ago

Pulmatrix reports Q3 EPS (71c) vs. ($1.03) last year

2024-11-08T15:35:10.000Z - 1 year ago

Pulmatrix sees cash runway into 4Q26

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

2024-08-13T13:08:29.000Z - 1 year ago

Pulmatrix reports Q2 EPS ($1.59) vs. ($1.04) last year

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 2 years ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

HomeRunHitterXXXXX May. 12 at 8:01 PM

$PULM scumbags couldn’t close it red today ya bunch of losers 😂

1 · Reply

Nakom May. 12 at 7:31 PM

$PULM You can’t tell me this stock is not being manipulated. Total BS.

0 · Reply

MinnieSteve3 May. 11 at 8:31 PM

$PULM Short interest rises from 19,602 shares on April 15 to 40,413 shares as of April 30. Granted, it's not huge but with the low daily trade volume it can dampen the share price.

1 · Reply

Nakom May. 11 at 6:05 PM

$PULM Couldn’t resist. Just picked up another 150 shares. I think big Pharma is going to be buying delivery platforms this year. JMO.

0 · Reply

Nakom May. 11 at 4:31 PM

$PULM I think with LQDA 1st quarter call Pulmatrix assets just got a whole lot more valuable. DPI is the way to go and a major Pharma is going to want the platform. JMO

1 · Reply

HomeRunHitterXXXXX May. 11 at 12:15 PM

$PULM stock is trading at its cash value

1 · Reply

texrex1230 May. 8 at 9:52 PM

$PULM Any idea on when the Shareholders meeting will be so we can approve the merger?

1 · Reply

Vinniesb May. 8 at 2:01 PM

$PULM Good Luck to whoever is trying to snag 20K shares on the bid!

1 · Reply

MinnieSteve3 May. 8 at 12:49 PM

$PULM a very quiet week. Something has to happen sometime.

1 · Reply

HomeRunHitterXXXXX May. 5 at 7:56 PM

$PULM up 6 cents on 34k volume not good

1 · Reply

Vinniesb May. 5 at 6:34 PM

$PULM Not Financial advice but my gap up radar is picking up some signals here!

1 · Reply

Nakom May. 5 at 4:50 PM

$PULM Picked up another 100 shares today. Couldn’t resist. All these small purchases sure do add up.

0 · Reply

Nakom May. 4 at 5:27 PM

$PULM you would have to be an idiot to sell at these prices. Good luck getting those 20,100. 🤣🤣🤣

1 · Reply

SuperGreenToday May. 4 at 3:50 PM

$PULM

2 · Reply

Nakom May. 4 at 3:40 PM

$PULM Dorsnt take much money to manipulate this stock. All good. 😊

0 · Reply

Nakom May. 4 at 1:46 PM

$PULM I would say this stock is wound pretty tight. Just like a rubber band airplane. ✈️. Once that propeller is let go this stock is going to take flight. Good luck chasing it.

1 · Reply

Nakom May. 1 at 3:40 PM

$PULM I wonder who is looking for 40,000 shares.

0 · Reply

Vinniesb May. 1 at 3:13 PM

$PULM 40,000 shares on the bid. That alone would take it over $2.00

0 · Reply

HomeRunHitterXXXXX May. 1 at 12:12 PM

$PULM can we get a run here to over 10?

2 · Reply

Nakom Apr. 30 at 5:45 PM

$PULM Even if you wanted to buy say 5000 shares at a much higher price they just are not available. What does that tell you.

0 · Reply

Nakom Apr. 30 at 3:59 PM

$PULM Shares are really drying up. 2 more months and everything should come to an end. All good on my end.

0 · Reply

Nakom Apr. 30 at 1:49 PM

$PULM who might be interested in owning Isperse. Merck, Cipla, MNKD, UTHR and the big lion in the room would be Eli Lily!!!

0 · Reply

Market Cap	4.57M
Revenue (ttm)	0.00
Net Income (ttm)	-5.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,900
Avg Vol	50,994
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	0%
Beta	1.94
Analysts	Strong Buy
Price Target	$10.00